US Patent 9273057 Imidazotriazinecarbonitriles useful as kinase inhibitors

Patent 9273057 was granted and assigned to Bristol-Myers Squibb on March, 2016 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Bristol-Myers Squibb

Current Assignee

Bristol-Myers Squibb

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

9273057

Date of Patent

March 1, 2016

Patent Application Number

14414152

Date Filed

July 12, 2013

Patent Citations Received

‌

US Patent 12134620 Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer

‌

US Patent 11878985 Substituted quinazolines as inhibitors of KRAS G12C

Patent Primary Examiner

‌

Venkataraman Balasubramanian

Patent abstract

The invention provides compounds of Formula (I)

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 9273057 Imidazotriazinecarbonitriles useful as kinase inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API